Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 67

Sort by

Sort Order Select

Journal Articles

PTPN11 Mutations Drive Tyrosine Kinase Inhibitor As Well As Venetoclax Resistance in Ph+ ALL Cells, but Are Sensitive to the Combination

Govinda Poudel, David T Yeung, Deborah L White, Timothy Hughes, Ilaria S Pagani

Blood (2022) 140 (Supplement 1): 3128–3129.

https://doi.org/10.1182/blood-2022-162194

Published: 2022

Journal Articles

A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income

Jerald P. Radich, Chung Hoow Kok, Ekaterina Yu. Chelysheva, Jorge E. Cortes, Qian Jiang, Michael Mauro, Dragana Milojkovic, Beatriz Moiraghi, Franck E. Nicolini, Matilda Ongondi, Katia B Pagnano, Daniela Žácková, Delphine Rea, Nicola Evans, Timothy Hughes

Blood (2022) 140 (Supplement 1): 9617–9619.

https://doi.org/10.1182/blood-2022-165855

Published: 2022

Journal Articles

ASC4FIRST: A Phase III Study of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Timothy Hughes, Jorge E. Cortes, Naoto Takahashi, Richard A. Larson, Ghayas C. Issa, Felice Bombaci, Nicholas Ramscar, Shruti Kapoor, Sophie Ifrah, Andreas Hochhaus

Blood (2022) 140 (Supplement 1): 6767–6768.

https://doi.org/10.1182/blood-2022-162249

Published: 2022

Journal Articles

Molecular Response of ≤10% BCR::ABL1 IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

Blood (2022) 140 (Supplement 1): 6760–6762.

https://doi.org/10.1182/blood-2022-157956

Published: 2022

Journal Articles

Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study

Timothy Hughes, Delphine Rea, Carla Boquimpani, Yosuke Minami, Michael Mauro, Jorge E. Cortes, Jane F. Apperley, Valentín García Gutiérrez, Shruti Kapoor, Alex Allepuz, Sarah Quenet, Yifan Zhang, Andreas Hochhaus

Blood (2022) 140 (Supplement 1): 6757–6759.

https://doi.org/10.1182/blood-2022-169110

Published: 2022

Journal Articles

Clonal Hematopoiesis Detected at the Time of Tyrosine Kinase Inhibitor Cessation Is Associated with Delayed Molecular Recurrence after Treatment-Free Remission in Patients with CML

Susan Branford, Naranie Shanmuganathan, Carol Wadham, Nur Hezrin Shahrin, Adelina Fernandes, Jinghua Feng, Andreas W Schreiber, Chung Hoow Kok, Verity A Saunders, Rob King, Ming Lin, Ilaria S Pagani, David T Yeung, David M Ross, Agnes S.M. Yong, Timothy Hughes

Blood (2022) 140 (Supplement 1): 3916–3917.

https://doi.org/10.1182/blood-2022-158735

Published: 2022

Journal Articles

Senolytic Therapy Can Reverse Senescent Bone Marrow Stroma of Therapy-Related Myeloid Neoplasm

Monika M Kutyna, Chung Hoow Kok, Yoon Lim, David Campbell, Sharon Paton, Chloe AL Thompson-Peach, Kelly SY Lim, Timothy Hughes, Sharad Kumar, Daniel Thomas, Stan Gronthos, Devendra Hiwase

Blood (2022) 140 (Supplement 1): 9755–9756.

https://doi.org/10.1182/blood-2022-167994

Published: 2022

Journal Articles

Clinical Outcomes of Chronic Myeloid Leukaemia (CML) Patients on Asciminib through the Managed Access Program (MAP) in Australia

Lynette C.Y. Chee, Nora Lee, Andrew Grigg, Melissa Chen, Anthony Schwarer, Jeff Szer, David T Yeung, Timothy Hughes, Naranie Shanmuganathan

Blood (2022) 140 (Supplement 1): 6800–6802.

https://doi.org/10.1182/blood-2022-163221

Published: 2022

Journal Articles

Additional Mutational Events at Diagnosis of CML Confer Inferior Failure-Free Survival and Molecular Response for Patients Treated with Frontline Imatinib but Not for Patients Treated with Frontline Second-Generation Tyrosine Kinase Inhibitors

Naranie Shanmuganathan, David T Yeung, Carol Wadham, Nur Hezrin Shahrin, Adelina Fernandes, Jinghua Feng, Verity A Saunders, Ming Lin, Rosalie Kenyon, Rob King, Paul Wang, David M Ross, Andreas W Schreiber, Timothy Hughes, Susan Branford

Blood (2022) 140 (Supplement 1): 805–806.

https://doi.org/10.1182/blood-2022-158743

Published: 2022

Journal Articles

Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA

Jorge E. Cortes, Timothy Hughes, Jan Geissler, Dong-Wook Kim, Elza Lomaia, Jiri Mayer, Anna G. Turkina, Sarah Hurwicz Kogut, Ana Paula Torres Cardoso, Monali Sura, Giuseppe Saglio

Blood (2022) 140 (Supplement 1): 195–197.

https://doi.org/10.1182/blood-2022-167177

Published: 2022

Journal Articles

Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CML

Blood (2022) 140 (Supplement 1): 192–194.

https://doi.org/10.1182/blood-2022-157244

Published: 2022

Journal Articles

First-in-Human Study of Elvn-001, a Highly Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients with Chronic Myeloid Leukemia Who Failed Previous Tyrosine Kinase Inhibitor Therapies

Timothy Hughes, Michael Mauro, Susan Branford, Wei Deng, Qi Wang, Helen Collins, Andreas Hochhaus

Blood (2022) 140 (Supplement 1): 6780–6781.

https://doi.org/10.1182/blood-2022-170401

Published: 2022

Journal Articles

A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial

Blood (2012) 120 (21): 163.

https://doi.org/10.1182/blood.V120.21.163.163

Published: 2012

Journal Articles

Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable BCR-ABL1 , a Criterion for Imatinib Discontinuation in Patients with CML

Susan Branford, PhD, David Ross, MBBS, PhD, Jodi Prime, BSc., Chani Field, BSc, Haley Altamura, BSc, Alexandra Yeoman, BSc, Jasmina Georgievski, BSc, Stuart Phillis, BSc, Bronte A Jamison, BSc, Brad Sullivan, BSc, David T Yeung, BSc, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS

Blood (2012) 120 (21): 165.

https://doi.org/10.1182/blood.V120.21.165.165

Published: 2012

Journal Articles

Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial

Blood (2012) 120 (21): 3747.

https://doi.org/10.1182/blood.V120.21.3747.3747

Published: 2012

Journal Articles

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA

Blood (2010) 116 (22): e111–e117.

https://doi.org/10.1182/blood-2010-06-291641

Published: 2010

Includes: Supplemental data

Journal Articles

A Worldwide Observational Registry Collecting Longitudinal Data on Management of Chronic Myeloid Leukemia Patients (The WORLD CML Registry) – 2nd Annual Interim Analysis

Ricardo Pasquini, MD, Jorge Cortes, MD, Hagop M. Kantarjian, MD, David Joske, MBBS, FRCPA, FRACP, Luis A Meillon, MD, Lidia Mongay, MD, PhD, MBA, John Reynolds, PhD, Timothy Hughes, MD, MBBS, Dong-Wook Kim, MD

Blood (2010) 116 (21): 2292.

https://doi.org/10.1182/blood.V116.21.2292.2292

Published: 2010

Journal Articles

Detection of Low Level Nilotinib or Dasatinib Resistant BCR-ABL Mutations by Mass Spectrometry In CML Patients Who Fail Imatinib Is Highly Predictive of Their Subsequent Clonal Expansion When Treated with the Drug for Which Their Mutation Confers Resistance

Wendy T Parker, PhD, Musei Ho, Rebecca M Lawrence, Darryl L Irwin, PhD, Hamish S Scott, PhD, Timothy Hughes, MD, MBBS, Susan Branford, PhD

Blood (2010) 116 (21): 891.

https://doi.org/10.1182/blood.V116.21.891.891

Published: 2010

Journal Articles

In Contrast to Imatinib, Dasatinib Intracellular Concentration In CML-CD34 + Progenitors Is Not Significantly Different Than That Observed In CD34 - Mature Cells.

Devendra K Hiwase, Jane Engler, Verity Saunders, Deborah L. White, PhD, Timothy Hughes, MD, MBBS

Blood (2010) 116 (21): 1205.

https://doi.org/10.1182/blood.V116.21.1205.1205

Published: 2010

Journal Articles

Mutation Analysis of BCR-ABL Tyrosine Kinase Domain In New Chronic Phase-Chronic Myeloid Leukemia Patients with Suboptimal Response or Treatment Failure From Imatinib Treatment.

Dong-Wook Kim, MD, Dongho Kim, Soo-Hyun Kim, Hyun-Gyung Goh, Fabrizio Pane, Timothy Hughes, Jerald P. Radich, Peter Lin, Giuseppe Saglio, Susan Branford, Giovanni Martinelli, Simona Soverini, Andreas Hochhaus

Blood (2010) 116 (21): 3441.

https://doi.org/10.1182/blood.V116.21.3441.3441

Published: 2010

NARROW

PTPN11 Mutations Drive Tyrosine Kinase Inhibitor As Well As Venetoclax Resistance in Ph+ ALL Cells, but Are Sensitive to the Combination

A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income

ASC4FIRST: A Phase III Study of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Molecular Response of ≤10% BCR::ABL1 IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study

Clonal Hematopoiesis Detected at the Time of Tyrosine Kinase Inhibitor Cessation Is Associated with Delayed Molecular Recurrence after Treatment-Free Remission in Patients with CML

Senolytic Therapy Can Reverse Senescent Bone Marrow Stroma of Therapy-Related Myeloid Neoplasm

Clinical Outcomes of Chronic Myeloid Leukaemia (CML) Patients on Asciminib through the Managed Access Program (MAP) in Australia

Additional Mutational Events at Diagnosis of CML Confer Inferior Failure-Free Survival and Molecular Response for Patients Treated with Frontline Imatinib but Not for Patients Treated with Frontline Second-Generation Tyrosine Kinase Inhibitors

Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA

Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CML

First-in-Human Study of Elvn-001, a Highly Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients with Chronic Myeloid Leukemia Who Failed Previous Tyrosine Kinase Inhibitor Therapies

A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial

Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable BCR-ABL1 , a Criterion for Imatinib Discontinuation in Patients with CML

Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA

A Worldwide Observational Registry Collecting Longitudinal Data on Management of Chronic Myeloid Leukemia Patients (The WORLD CML Registry) – 2nd Annual Interim Analysis

Detection of Low Level Nilotinib or Dasatinib Resistant BCR-ABL Mutations by Mass Spectrometry In CML Patients Who Fail Imatinib Is Highly Predictive of Their Subsequent Clonal Expansion When Treated with the Drug for Which Their Mutation Confers Resistance

In Contrast to Imatinib, Dasatinib Intracellular Concentration In CML-CD34 + Progenitors Is Not Significantly Different Than That Observed In CD34 - Mature Cells.

Mutation Analysis of BCR-ABL Tyrosine Kinase Domain In New Chronic Phase-Chronic Myeloid Leukemia Patients with Suboptimal Response or Treatment Failure From Imatinib Treatment.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only